Literature DB >> 15816153

The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection.

L J White1, M Waris, P A Cane, D J Nokes, G F Medley.   

Abstract

Human respiratory syncytial virus (hRSV) transmission dynamics are inherently cyclical, and the observed genetic diversity (between groups A and B) also appears to have a repeating pattern. A key unknown is the extent to which genetic variants interact immunologically, and thus impact on epidemiology. We developed a novel mathematical model for hRSV transmission including seasonal forcing of incidence and temporary intra- and inter-group partial immunity. Simultaneous model fits to data from two locations (England & Wales, UK, and Turku, Finland) successfully reproduced the contrasting infection dynamics and group A/B dominance patterns. Parameter estimates are consistent with direct estimates. Differences in the magnitude and seasonal variation in contact rate between the two populations alone could account for the variation in dynamics between these populations. The A/B group dominance patterns are explained by reductions in susceptibility to and infectiousness of secondary homologous and heterologous infections. The consequences of the observed dynamic complexity are discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15816153      PMCID: PMC2870247          DOI: 10.1017/s0950268804003450

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  52 in total

1.  Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions.

Authors:  Virginia E Pitzer; Manish M Patel; Ben A Lopman; Cécile Viboud; Umesh D Parashar; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

2.  Molecular analysis of respiratory syncytial virus reinfections in infants from coastal Kenya.

Authors:  Paul D Scott; Rachel Ochola; Mwanajuma Ngama; Emelda A Okiro; D James Nokes; Graham F Medley; Patricia A Cane
Journal:  J Infect Dis       Date:  2005-11-17       Impact factor: 5.226

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Cross-immunity between strains explains the dynamical pattern of paramyxoviruses.

Authors:  Samit Bhattacharyya; Per H Gesteland; Kent Korgenski; Ottar N Bjørnstad; Frederick R Adler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

5.  Vaccination strategies against respiratory syncytial virus.

Authors:  Dan Yamin; Forrest K Jones; John P DeVincenzo; Shai Gertler; Oren Kobiler; Jeffrey P Townsend; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 6.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

Review 7.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 8.  Respiratory syncytial virüs infections in neonates and infants.

Authors:  Yıldız Perk; Mine Özdil
Journal:  Turk Pediatri Ars       Date:  2018-06-01

9.  Increased frequency of travel in the presence of cross-immunity may act to decrease the chance of a global pandemic.

Authors:  R N Thompson; C P Thompson; O Pelerman; S Gupta; U Obolski
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-06-24       Impact factor: 6.237

10.  Duration of shedding of respiratory syncytial virus in a community study of Kenyan children.

Authors:  Emelda A Okiro; Lisa J White; Mwanajuma Ngama; Patricia A Cane; Graham F Medley; D James Nokes
Journal:  BMC Infect Dis       Date:  2010-01-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.